<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joaquim Bellmunt, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Gupta, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Lerner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Worldwide, bladder cancer accounts for almost 600,000 new cases and over 200,000 deaths [<a href="#rid1">1</a>]. In developed areas of the world, such as North America and Western Europe, these bladder cancers are predominantly urothelial carcinoma. (See  <a class="medical medical_review" href="/z/d/html/2957.html" rel="external">"Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder", section on 'Epidemiology'</a>.)</p><p>The preferred management of patients with muscle-invasive bladder cancer consists of a multimodal approach comprising neoadjuvant chemotherapy followed by radical cystectomy. In appropriately selected patients who are not candidates for radical cystectomy or who prefer to retain their native bladder, a combined-modality approach of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy is an alternative.</p><p>This topic discusses neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive urothelial bladder cancer. Other treatment approaches to urothelial bladder cancer are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98344.html" rel="external">"Bladder preservation treatment options for muscle-invasive urothelial bladder cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2966.html" rel="external">"Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2974.html" rel="external">"Radical cystectomy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract"</a>.)</p><p></p><p class="headingAnchor" id="H210939004"><span class="h1">OVERVIEW OF TREATMENT APPROACH</span><span class="headingEndMark"> — </span>All patients must be clinically staged prior to initiation of treatment for bladder cancer. This typically includes computed tomography (CT) of the chest, abdomen, and pelvis, and cystoscopy with transurethral resection of bladder tumor (TURBT). The diagnosis and staging of urothelial carcinoma is covered separately. (See  <a class="medical medical_review" href="/z/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer", section on 'Initial evaluation'</a>.)</p><p>Radical cystectomy with bilateral pelvic lymphadenectomy remains the standard of care for patients with muscle-invasive bladder cancer. However, the high relapse rates following cystectomy alone for patients with muscle-invasive bladder cancer have led to the use of neoadjuvant treatment [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with muscle-invasive bladder cancer who will undergo a radical cystectomy, cisplatin-based neoadjuvant chemotherapy is indicated. The use of neoadjuvant chemotherapy improves survival in this population. (See <a class="local">'Neoadjuvant chemotherapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapy should be initiated expeditiously in appropriate candidates. In an observational study of over 2200 patients from the National Cancer Database, a delay in neoadjuvant chemotherapy of ≥8 weeks from diagnosis was associated with upstaging [<a href="#rid3">3</a>]. It also suggested that radical cystectomy should be performed within 7 months of initial diagnosis, for optimal results. However, it should be noted that delay was also associated with African American race, Medicaid insurance, and academic facilities (which may have reflected their safety-net roles), and it is possible that there were other confounding variables that were not identified prospectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For select patients with muscle-invasive bladder cancer who are not candidates for radical cystectomy or who desire preservation of their native bladder, radiation therapy (RT) plus concurrent chemotherapy is indicated rather than chemotherapy or RT as a single-modality treatment. (See  <a class="medical medical_review" href="/z/d/html/98344.html" rel="external">"Bladder preservation treatment options for muscle-invasive urothelial bladder cancer", section on 'Patient selection'</a>.)</p><p></p><p class="headingAnchor" id="H210939438"><span class="h1">NEOADJUVANT CHEMOTHERAPY</span><span class="headingEndMark"> — </span>For patients undergoing neoadjuvant chemotherapy, cisplatin-based combination regimens should be used. The most commonly used neoadjuvant regimens are dose-dense MVAC (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef111814" href="/z/d/graphic/111814.html" rel="external">table 1</a>)) and <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus cisplatin. Further data are needed to establish the optimal regimen. (See <a class="local">'Choice of chemotherapy regimens'</a> below.)</p><p>The administration of neoadjuvant cisplatin-based chemotherapy has consistently demonstrated a survival benefit when given prior to surgery [<a href="#rid4">4,5</a>]. This was demonstrated in a meta-analysis of 11 randomized trials that compared cisplatin-based neoadjuvant chemotherapy plus local therapy with local therapy alone [<a href="#rid4">4</a>]. Compared with local therapy alone, neoadjuvant cisplatin-based combination chemotherapy resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>An improvement in overall survival (five-year overall survival 50 versus 45 percent, hazard ratio [HR] 0.87, 95% CI 0.78-0.98).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lower risk of recurrence (HR for recurrence 0.81, 95% CI 0.74-0.9). This translated into an absolute disease-free survival (DFS) benefit of 7 percent.</p><p></p><p class="headingAnchor" id="H11226260"><span class="h2">Choice of chemotherapy regimens</span><span class="headingEndMark"> — </span>There is no established ideal neoadjuvant chemotherapy regimen. Further follow-up of survival in a randomized trial comparing the most frequently used regimens (dose-dense MVAC and <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [GC]) are necessary to help guide this decision [<a href="#rid6">6,7</a>]. </p><p>In the absence of a definitive standard of care, we prefer dose-dense MVAC in young patients with good performance status and no comorbidities, as this approach shortens the time from diagnosis to surgery. In older patients and those unable to tolerate this combination due to medical comorbidities, GC is a reasonable alternative. </p><p>The most commonly employed regimens administered in the neoadjuvant setting are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose-dense MVAC </strong>– <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (30 mg/m<sup>2</sup> on day 1), <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a> (3 mg/m<sup>2</sup> on day 2), <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> (30 mg/m<sup>2</sup> on day 2), <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (70 mg/m<sup>2</sup> on day 2), <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">filgrastim</a> (240 mcg/m<sup>2</sup> subcutaneously on days 4 to 10), repeated every 14 days, if toxicity permits, for three to six cycles  (<a class="graphic graphic_table graphicRef111814" href="/z/d/graphic/111814.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GC </strong>– <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> (1000 mg/m<sup>2</sup> on days 1, 8) plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (70 mg/m<sup>2 </sup>on day 1) given every 21 days for a maximum of four cycles  (<a class="graphic graphic_table graphicRef128074" href="/z/d/graphic/128074.html" rel="external">table 2</a>) [<a href="#rid8">8</a>]. (See <a class="local">'GC'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a creatinine clearance between 50 and 60 mL/min may be offered an alternative regimen of <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> (1000 mg/m<sup>2</sup> on days 1, 8) plus split-dose <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (35 mg/m<sup>2 </sup>on days 1, 8) given every 21 days for a maximum of four cycles [<a href="#rid9">9,10</a>]. </p><p></p><p>Regimens that are less commonly used in the neoadjuvant setting are: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV </strong>– <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (30 mg/m<sup>2</sup>) and <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a> (4 mg/m<sup>2</sup>) on days 1 and 8 plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (100 mg/m<sup>2 </sup>on day 2), with <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (15 mg every six hours for four doses) on days 2 and 9, repeated every 28 days for three cycles [<a href="#rid11">11</a>]. (See <a class="local">'CMV'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic MVAC </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (30 mg/m<sup>2</sup> on days 1, 15, and 22), <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a> (3 mg/m<sup>2</sup> on days 2, 15, and 22), <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> (30 mg/m<sup>2</sup> on day 2), and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (70 mg/m<sup>2 </sup>on day 2) administered every 28 days for three cycles  (<a class="graphic graphic_table graphicRef64950" href="/z/d/graphic/64950.html" rel="external">table 3</a>) [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1">However, classic MVAC is no longer recommended as neoadjuvant chemotherapy by the NCCN [<a href="#rid13">13</a>]. (See <a class="local">'MVAC'</a> below.)</p><p></p><p>Data comparing these regimens come from randomized trials and observational studies [<a href="#rid6">6,7,14-18</a>].</p><p>Dose-dense MVAC was compared with GC in an open-label phase III trial (GETUG/AFU V05 VESPER) of 493 patients with non-metastatic muscle-invasive bladder cancer [<a href="#rid6">6,7,19</a>]. In this study, patients were randomly assigned to either six cycles of dose-dense MVAC or four cycles of GC administered before or after radical cystectomy. Among the 437 patients (88 percent) with clinical T2 to T4a, node-negative disease treated with neoadjuvant chemotherapy, approximately 90 percent underwent cystectomy. The remaining 56 patients (12 percent) received adjuvant therapy after cystectomy. </p><p>At median follow-up of 40 months, results were as follows [<a href="#rid7">7</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>All patients </strong>– For the entire study population, compared with GC, dose-dense MVAC had similar three-year progression-free survival (PFS; 64 versus 56 percent, HR 0.77, 95% CI 0.57-1.02) and improved time to progression (TTP; 69 versus 58 percent, HR 0.68, 95% CI 0.50-0.93). Overall survival data are immature. Data were inconclusive for those who received adjuvant therapy due to the limited number of patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neoadjuvant therapy </strong>– Among the subgroup treated with neoadjuvant therapy, dose-dense MVAC improved three-year PFS compared with GC (66 versus 56 percent, HR 0.70, 95% CI 0.51-0.96) [<a href="#rid7">7</a>]. There was no difference in the pathologic complete response (pCR) rate between the two chemotherapy regimens (42 versus 36 percent) [<a href="#rid6">6</a>]. However, dose-dense MVAC increased local control rates over GC, including non-muscle invasive (&lt;ypT2pN0; 63 versus 49 percent) and organ-confined disease (&lt;ypT3pN0; 77 versus 63 percent) [<a href="#rid6">6,7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity </strong>– Grade ≥3 toxicity was higher for dose-dense MVAC compared with GC, including gastrointestinal toxicities and asthenia [<a href="#rid6">6</a>]. Only 60 percent of patients completed the planned six cycles of dose-dense MVAC due to toxicity [<a href="#rid7">7</a>]. </p><p></p><p>In a separate randomized phase II SWOG S1314 trial (Co-expression Extrapolation [COXEN]) of 237 patients with muscle-invasive bladder cancer, pCR rates were also similar for dose-dense MVAC compared with GC (28 versus 30 percent) [<a href="#rid16">16</a>]. In preliminary results, OS and PFS were also similar for dose-dense MVAC compared with GC [<a href="#rid20">20</a>]. (See <a class="local">'Gene expression profiling'</a> below.)</p><p>Observational studies have not identified a substantive difference in pCR rates between neoadjuvant classic dosing of MVAC and GC [<a href="#rid14">14,15</a>]. As an example, one observational study from 19 centers in North America and Europe evaluated 935 patients treated with neoadjuvant chemotherapy for muscle-invasive (T2 to T4a), clinically node-negative (N0) bladder cancer [<a href="#rid15">15</a>]. Chemotherapy consisted of GC in 64 percent of cases, MVAC in 20 percent, and other regimens in 15 percent. The rate of pCR was similar between those treated with GC and MVAC (approximately 24 percent for each group). While the pCR rates for MVAC in this study are lower than that seen in randomized studies, such as the INT-0800 trial (38 percent) and the GETUG/AFU V05 VESPER trial (42 percent), this likely reflects selection bias and variations in staging/diagnostic work-up in the underlying patient populations. </p><p class="headingAnchor" id="H971959904"><span class="h2">MVAC</span><span class="headingEndMark"> — </span>Classic MVAC is the best-studied regimen for neoadjuvant chemotherapy. Dose-dense MVAC regimens have been studied in an effort to further improve upon survival results.</p><p class="headingAnchor" id="H11225791"><span class="h3">Classic MVAC</span><span class="headingEndMark"> — </span>The benefit and toxicity of MVAC was most conclusively demonstrated in the INT-0080 trial, which enrolled 307 patients with T2 to T4a bladder cancer and randomly assigned patients to three 28-day cycles of MVAC prior to radical cystectomy or surgery alone [<a href="#rid12">12</a>].</p><p>Compared with surgery alone, neoadjuvant MVAC resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>A statistically significant increase in the pCR rate (38 versus 15 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trend toward improvement in overall survival (median, 77 versus 46 months, five-year survival rate 57 versus 43 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high rate of serious (grade 3/4) hematologic or gastrointestinal toxicity, including neutropenia (57 percent), stomatitis (10 percent), and nausea and vomiting (6 percent)</p><p></p><p class="headingAnchor" id="H547096410"><span class="h3">Dose-dense MVAC</span><span class="headingEndMark"> — </span>Data suggest that dose-dense MVAC is active when administered in the neoadjuvant setting for patients with muscle-invasive bladder cancer. Given the shortened time to surgery with the use of this modified regimen, we believe this represents one option with a reasonable treatment schedule.</p><p>Two single-arm phase II studies suggest that this dose-dense MVAC is feasible in the neoadjuvant setting [<a href="#rid21">21,22</a>]. In both, eligible patients had clinical stage T2 to T4 muscle-invasive bladder cancer; patients with a single lymph node up to 2 cm in greatest dimension on imaging (clinical N1) were also allowed to participate.</p><p class="bulletIndent1"><span class="glyph">●</span>One phase II trial included 39 patients (43 percent with N1 disease) who were treated with four cycles of dose-dense MVAC treatment [<a href="#rid21">21</a>]. Overall, 95 percent completed all four cycles of treatment. The pathologic response rate was 49 percent (19 of 39 patients), with a pCR in 10 patients. At a median follow-up of 24 months, the disease-free rate at one year was higher among those who achieved a pathologic response (89 versus 67 percent among those without one; HR 2.6, 95% CI 0.8-8.1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second phase II trial included 40 evaluable patients (7 percent with N1 disease) who were treated with three cycles of accelerated MVAC therapy [<a href="#rid22">22</a>]. The pCR rate was 38 percent, and another six patients (14 percent) were downstaged to non-muscle invasive disease at the time of cystectomy. A pathologic response to neoadjuvant MVAC therapy was associated with significant prolongation of both disease-free and overall survival.</p><p></p><p>Data comparing neoadjuvant dose-dense MVAC versus GC are discussed above. (See <a class="local">'Choice of chemotherapy regimens'</a> above.)</p><p>Increasing the dose intensity of MVAC by administering treatment every two weeks with granulocyte colony-stimulating factor (G-CSF) support has been extensively evaluated in patients with metastatic or advanced urothelial cancer. In the European Organisation for Research and Treatment of Cancer (EORTC) 30924 trial of patients with locally advanced or metastatic urothelial carcinoma, this approach increased progression-free survival, but it did not result in a statistically significant difference in overall survival, although it suggested that toxicity was less severe [<a href="#rid23">23</a>]. Subsequent follow-up from that trial found that the overall survival rate at five years was 21.8 percent with dose-dense MVAC versus 13.5 percent with classic MVAC [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract", section on 'MVAC'</a>.)</p><p class="headingAnchor" id="H2959662713"><span class="h3">Classic MVAC versus dose-dense MVAC</span><span class="headingEndMark"> — </span>Dose-dense MVAC may be favored over classic MVAC due to the reduced toxicity reported for dose-dense MVAC in the metastatic setting, as described in the European Organisation for Research and Treatment of Cancer (EORTC) randomized trial. Additionally, classic MVAC is no longer recommended as neoadjuvant chemotherapy by the NCCN [<a href="#rid13">13</a>]. (See <a class="local">'MVAC'</a> above.)</p><p class="headingAnchor" id="H1191648640"><span class="h2">GC</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (GC) is an option for neoadjuvant treatment of muscle-invasive bladder cancer  (<a class="graphic graphic_table graphicRef128074" href="/z/d/graphic/128074.html" rel="external">table 2</a>). In patients with metastatic urothelial cancer, GC has similar efficacy and less toxicity compared with MVAC. However, a nonsignificant trend toward greater activity was observed with MVAC. (See  <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract", section on 'Gemcitabine plus cisplatin'</a>.)</p><p>Data comparing neoadjuvant GC with dose-dense MVAC are discussed above. (See <a class="local">'Choice of chemotherapy regimens'</a> above.)</p><p class="headingAnchor" id="H11225845"><span class="h2">CMV</span><span class="headingEndMark"> — </span>Neoadjuvant CMV was evaluated in a phase III study involving 976 patients with high-grade T2-T4aN0-NXM0 bladder cancer who were randomly assigned to three cycles of CMV or no chemotherapy. All patients were then managed according to each institution's choice (ie, radical cystectomy or radiation therapy) [<a href="#rid11">11</a>]. Neoadjuvant treatment with CMV resulted in a pCR rate of 33 percent. With a median follow-up of eight years, neoadjuvant CMV was associated with a reduction in the risk of death compared with local treatment alone (HR 0.84, 95% CI 0.72-0.99) [<a href="#rid25">25</a>]. This corresponds with an absolute improvement in overall survival at 10 years of 6 percent (30 to 36 percent).</p><p class="headingAnchor" id="H365740882"><span class="h2">Patients with kidney function impairment</span><span class="headingEndMark"> — </span>For patients with kidney function impairment (creatinine clearance between 50 and 60 mL/min) may be offered <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus split-dose <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef128074" href="/z/d/graphic/128074.html" rel="external">table 2</a>) [<a href="#rid9">9,10</a>]. (See <a class="local">'Choice of chemotherapy regimens'</a> above.)</p><p>Studies have also evaluated replacing <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> in patients with kidney function impairment [<a href="#rid26">26</a>]. However, there are no randomized data supporting the use of carboplatin for the treatment of bladder cancer in the neoadjuvant setting. </p><p>Patients with bladder cancer who present with kidney function impairment should be evaluated for a renal tract obstruction. Renal tract obstruction is a commonly encountered problem among patients with bladder cancer, especially if the tumor is located adjacent to one or both ureteric orifices. All patients with an obstruction should undergo ureteral stent placement or a percutaneous nephrostomy as an attempt to restore normal kidney function, which could then allow for the administration of standard doses of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. (See  <a class="medical medical_review" href="/z/d/html/15182.html" rel="external">"Placement and management of indwelling ureteral stents"</a>.)</p><p>Despite promising preclinical evidence to support the activity of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> for urothelial cancer [<a href="#rid27">27</a>], randomized data suggest that carboplatin is inferior to <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid28">28-31</a>]. For example, in a randomized phase II trial conducted by the Eastern Cooperative Oncology Group (ECOG), single-agent carboplatin resulted in a low response rate with a median overall survival of only five months [<a href="#rid29">29</a>]. In a separate randomized trial of 47 patients with advanced bladder cancer, compared with MVAC (a cisplatin-based regimen), the M-CAVI regimen (carboplatin, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>) had lower objective response rates [<a href="#rid32">32</a>]. Subsequent trials evaluated carboplatin as a single agent [<a href="#rid30">30</a>], in combination with <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid33">33</a>], and in combination with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid26">26</a>]. Such combinations (particularly carboplatin plus gemcitabine) appear to have substantial anti-tumor activity against urothelial malignancies [<a href="#rid33">33</a>] but are not considered to be optimal therapies in patients eligible for cisplatin-based chemotherapy.</p><p class="headingAnchor" id="H3763941324"><span class="h2">Thromboembolic complications</span><span class="headingEndMark"> — </span>Patients with cancer are at increased risk for thromboembolic events. A meta-analysis of bladder cancer patients found that the one-year risk was elevated approximately fivefold compared with the general population [<a href="#rid34">34</a>]. Currently, guidelines recommend prophylaxis for cancer patients who undergo pelvic or abdominal surgery. (See  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p>The risk may be further elevated in patients who undergo preoperative neoadjuvant chemotherapy [<a href="#rid35">35</a>]. In a retrospective multicenter analysis of 761 patients treated with neoadjuvant chemotherapy followed by radical cystectomy, the overall incidence of thromboembolic events (primarily deep venous thrombosis and pulmonary embolism) was 13.8 percent; in 58 percent of cases, the thromboembolic event occurred during neoadjuvant chemotherapy and prior to radical cystectomy.</p><p>Additional prospective evaluation is required to determine if prophylaxis is beneficial during neoadjuvant chemotherapy.</p><p class="headingAnchor" id="H1370258074"><span class="h1">IS THERE A ROLE FOR NEOADJUVANT IMMUNOTHERAPY?</span><span class="headingEndMark"> — </span>There is interest in investigating the use of checkpoint inhibitor immunotherapy as neoadjuvant therapy, given its efficacy in the treatment of metastatic urothelial cancer. Further randomized trials are necessary before incorporating neoadjuvant immunotherapy into routine clinical practice. (See  <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract"</a>.)</p><p>Most studies investigating neoadjuvant immunotherapy have been performed in patients who are ineligible for cisplatin-based chemotherapy [<a href="#rid36">36</a>]. Complete pathologic response rates between approximately 30 to 40 percent have been reported in early phase I/II studies using neoadjuvant <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> (ABACUS) [<a href="#rid37">37,38</a>], <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> (PURE-01) [<a href="#rid39">39-41</a>], the combination of <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> and <a class="drug drug_general" data-topicid="139983" href="/z/d/drug information/139983.html" rel="external">tremelimumab</a> [<a href="#rid42">42</a>], and <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid43">43</a>]. </p><p>Pathologic complete response rates have also been seen in patients receiving immunotherapy in combination with cisplatin-based chemotherapy prior to radical cystectomy [<a href="#rid44">44,45</a>]. As an example, in nonrandomized phase II trial, the addition of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> to neoadjuvant <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus split-dose <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> resulted in a complete pathologic response rate of 36 percent [<a href="#rid44">44</a>]. In preliminary results from a separate phase II trial (BLASST-1), the addition of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> to neoadjuvant gemcitabine plus cisplatin resulted in a complete pathologic response rate of 50 percent [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1244259799"><span class="h1">IS THERE A ROLE FOR NEOADJUVANT RADIATION THERAPY?</span><span class="headingEndMark"> — </span>Neoadjuvant radiation should not be used in patients with muscle-invasive bladder cancer prior to radical cystectomy.</p><p>As a single modality, preoperative radiation therapy (RT) can eradicate disease in a small proportion of patients undergoing cystectomy [<a href="#rid47">47,48</a>]. However, subsequent randomized trials demonstrated that while preoperative RT can improve local control, it has no impact on survival when compared with cystectomy alone [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H611321449"><span class="h1">ADJUVANT THERAPY</span><span class="headingEndMark"> — </span>Although neoadjuvant chemotherapy is associated with a significant survival advantage, not all patients with muscle-invasive bladder cancer who undergo radical cystectomy are treated with neoadjuvant chemotherapy. In such patients, the approach to adjuvant systemic therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2966.html" rel="external">"Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder"</a>.)</p><p class="headingAnchor" id="H501917112"><span class="h1">RADICAL CYSTECTOMY</span><span class="headingEndMark"> — </span>At the completion of neoadjuvant chemotherapy, patients should proceed with radical cystectomy regardless of the clinical response, unless there is the development of biopsy-proven metastatic disease. Although neoadjuvant chemotherapy results in a high response rate, the presence of persistent disease can only be assessed by cystectomy. (See  <a class="medical medical_review" href="/z/d/html/2974.html" rel="external">"Radical cystectomy"</a>.)</p><p>When feasible, our approach is to reassess the extent of disease with computed tomography (CT) scan after two doses of neoadjuvant chemotherapy to ensure adequate response to cytotoxic treatment prior to continuing. If the tumor has progressed, cystectomy should be discussed with the patient, unless distant metastases have developed, in which case the patient should be treated for metastatic disease. (See  <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract"</a>.)</p><p>The risk of residual disease despite a clinical complete response was illustrated by the Southwest Oncology Group (SWOG) trial S0219, in which 77 patients with T2 to T4a bladder cancer were treated with three cycles of <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, and <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, followed by restaging [<a href="#rid51">51</a>]. Following chemotherapy, 34 patients (46 percent) had a clinical complete response, ten of whom underwent an immediate cystectomy. Of these ten, six had persistent tumor in the cystectomy specimen.</p><p>Although it might be possible to identify patients who may not require cystectomy at the end of neoadjuvant chemotherapy, the data to support a tailored postneoadjuvant surgical approach are limited. In one study of 104 patients with T2 to T4aNx urothelial cancer, all of whom received three courses of neoadjuvant MVAC (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>), all patients underwent clinical restaging at the end of treatment and selective surgical treatment was performed [<a href="#rid52">52</a>]. The main results were:</p><p class="bulletIndent1"><span class="glyph">●</span>Of those who underwent transurethral resection of bladder tumor (TURBT) only (n = 49), 37 had a pathologic complete response (pCR). The five-year survival rate for the group was 67 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of those who underwent partial cystectomy for a residual monofocal lesion after chemotherapy (n = 13), five patients recurred (two with superficial and three with locally invasive disease). The five-year survival rate was 69 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of those who underwent radical cystectomy for persistent disease at the end of neoadjuvant treatment (n = 39), 14 developed metastatic disease. The five-year survival rate was 46 percent.</p><p></p><p>The outcome for those who do not undergo immediate radical cystectomy was studied in a retrospective series of 48 patients who had a clinical complete response to neoadjuvant platinum-based chemotherapy [<a href="#rid53">53</a>]. Seven patients underwent immediate radical cystectomy, while 41 elected bladder preservation with close surveillance. Of these 41 patients, 19 relapsed (46 percent), with a median time to recurrence of 5.4 months. The five-year rates of cancer-specific survival, disease-free survival, and cystectomy-free survival were 87, 58, and 79 percent, respectively. It is important to note that case selection bias may have been an important determinant of outcome in this study.</p><p>Given these findings, we and others consider bladder preservation inferior to radical cystectomy when attempting to render patients treated with neoadjuvant therapy disease free.</p><p class="headingAnchor" id="H210940629"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Pathologic complete response (pCR) following neoadjuvant chemotherapy is associated with improved disease-free and overall survival. As an example, in the Southwest Oncology Group trial of MVAC (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) plus cystectomy versus cystectomy alone, the median survival of patients with a pCR was not reached among those treated with MVAC prior to cystectomy [<a href="#rid12">12</a>]. For those with residual disease, median survival was four years. (See  <a class="medical medical_review" href="/z/d/html/2974.html" rel="external">"Radical cystectomy", section on 'Prognostic factors for survival'</a>.)</p><p>In addition, the prognostic impact of chemotherapy (whether administered before or after surgery) is likely complicated by factors beyond the use of this treatment modality, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The prognosis of any given patient may depend as much on where a patient was treated as what treatment they received. For example, in one study, the outcome of patients with T2a or T2b urothelial cancer treated with surgery alone at one center was better than what has been previously reported in other series that used combined-modality treatment [<a href="#rid54">54</a>]. However, this was a single-center study, and it is not clear whether there was an impact from occult case selection bias, despite the very large number of cases reported. It has repeatedly been established that high case volume is associated with better outcomes, suggesting benefits from referral to centers of excellence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The staging of bladder cancer by the American Joint Committee on Cancer (AJCC) has evolved over the years, and thus, it becomes difficult to compare between older and more contemporary clinical trials. This illustrates the importance of randomized trials in preference to historical comparisons.</p><p></p><p class="headingAnchor" id="H210941663"><span class="h1">POSTTREATMENT SURVEILLANCE AND TREATMENT</span><span class="headingEndMark"> — </span>For patients who have completed treatment for muscle-invasive bladder cancer, follow-up is essential for detection of a recurrence (in the case of partial cystectomy or bladder preservation) or a second primary urothelial tumor along the urogenital tract. Posttreatment surveillance depends on whether cystectomy or bladder preservation was performed. This is discussed in detail separately (see  <a class="medical medical_review" href="/z/d/html/2978.html" rel="external">"Overview of the initial approach and management of urothelial bladder cancer", section on 'Posttreatment surveillance'</a>). In summary:</p><p>Patients who were treated with cystectomy should be evaluated every three months for the first year, every six months for the second and third years, and then annually to year 5. After this, evaluations should be guided by clinical findings. The evaluation typically consists of lab work (ie, urine cytology, liver and renal function tests, and electrolytes) and imaging with computed tomography (CT) of the chest, abdomen, and pelvis.</p><p class="headingAnchor" id="H13"><span class="h1">INVESTIGATIONAL APPROACHES</span></p><p class="headingAnchor" id="H14"><span class="h2">p53 status for risk-directed clinical trials</span><span class="headingEndMark"> — </span>Mutations in the tumor suppressor gene, p53 have been evaluated as a way to select patients for treatment. However, we recommend against routine study of p53 expression prior to neoadjuvant therapy outside an investigational setting.</p><p>Despite promising early data that had begun to influence clinical practice, the association between p53 mutations and a poor prognosis in bladder cancer has not been consistently demonstrated [<a href="#rid55">55-61</a>]. As an example, in one study involving 243 patients who underwent cystectomy for pTa to pT4B disease, the presence of p53-altered immunoreactivity compared with p53 wild-type was associated with a significantly higher risk of both disease recurrence and death [<a href="#rid55">55</a>]. Recurrence rates for tumors with and without detectable p53 immunoreactivity were 62 versus 7 percent for pT1 tumors, 56 versus 12 percent for pT2 tumors, and 80 versus 11 percent for pT3 tumors. However, other studies failed to confirm the prognostic significance of p53 mutation, and currently its role remains uncertain in view of the inconsistent and conflicting published data. Although there are occasional reports of nonrandomized trials that claim utility of p53 profiling, we believe that there is still no routine place for this outside the context of a clinical trial or investigative protocol.</p><p>One adjuvant trial attempted to select bladder cancer patients with pathologic organ-confined tumors positive for mutant p53 and randomly assign treatment with observation or adjuvant chemotherapy with MVAC (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>). However, this trial was closed at interim analysis due to futility and is reported as a negative trial [<a href="#rid60">60</a>]. This trial is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2966.html" rel="external">"Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder", section on 'Patients eligible for cisplatin-based chemotherapy'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Gene expression profiling</span><span class="headingEndMark"> — </span>The use of individual patient gene expression patterns to predict individual responsiveness to neoadjuvant chemotherapy is an area of active investigation [<a href="#rid62">62,63</a>]. The role of gene expression profiling in the molecular prognostication of invasive bladder cancer remains experimental.</p><p class="bulletIndent1"><span class="glyph">●</span>Several important clinical trials may provide guidance on the implementation of personalized medicine in invasive bladder cancer. As an example, a randomized phase II trial (S1314) evaluated the utility of the Co-Expression Extrapolation (COXEN) biomarker. COXEN is a panel of tumor-specific genes generated by a computer program to predict a pT0 rate in patients with localized muscle-invasive bladder cancer treated with a specific neoadjuvant cisplatin-based chemotherapy followed by cystectomy [<a href="#rid16">16</a>]. In preliminary results from this trial, COXEN scores for GC or MVAC were not associated with improved OS within their respective treatment arms, although the COXEN-GC score was associated with improved OS among patients who received either regimen [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study, whole transcriptome profiling was performed on transurethral resection specimens from 343 patients with muscle-invasive bladder cancer prior to treatment with neoadjuvant chemotherapy. Molecular subtyping appeared to have an impact on the selection of patients who benefit from neoadjuvant chemotherapy. These data also suggested that patients with basal tumors should be prioritized for neoadjuvant chemotherapy [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An emerging area of focus is the impact of mutations of DNA repair genes (eg, <em>BRCA1</em>, <em>BRCA2</em>,<em> ATM</em>,<em> ERCC2</em>,<em> RB1</em>,<em> FANCC </em>[<a href="#rid65">65,66</a>]), which may correlate with response to chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another important innovation has been the demonstration of the importance of programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in advanced bladder cancer [<a href="#rid67">67</a>]. Data suggest that PD-L1 expression after neoadjuvant chemotherapy is associated with prolonged survival [<a href="#rid68">68</a>], and this biomarker remains under investigation.</p><p></p><p class="bulletIndent1">Further data on neoadjuvant immunotherapy for bladder cancer are discussed above. (See <a class="local">'Is there a role for neoadjuvant immunotherapy?'</a> above.)</p><p></p><p class="headingAnchor" id="H1262575961"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122007.html" rel="external">"Society guideline links: Bladder cancer"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/870.html" rel="external">"Patient education: Bladder cancer treatment; muscle invasive cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach </strong>– Radical cystectomy and bilateral pelvic lymphadenectomy remain the standard of care for patients with muscle-invasive bladder cancer. For patients with T2 to T4a bladder cancer  (<a class="graphic graphic_figure graphicRef133156" href="/z/d/graphic/133156.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef110763" href="/z/d/graphic/110763.html" rel="external">table 4</a>) for whom a radical cystectomy is planned, we recommend neoadjuvant chemotherapy prior to cystectomy over surgery alone (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Neoadjuvant chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of neoadjuvant chemotherapy regimen </strong>– For patients receiving neoadjuvant chemotherapy, the optimal regimen is not established. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most commonly used treatment options are dose-dense MVAC (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef111814" href="/z/d/graphic/111814.html" rel="external">table 1</a>)) and <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus cisplatin (GC  (<a class="graphic graphic_table graphicRef128074" href="/z/d/graphic/128074.html" rel="external">table 2</a>)).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with good performance status, we suggest dose-dense MVAC (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) over GC (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, for older patients and those unable to tolerate dose-dense MVAC due to medical comorbidities, GC  (<a class="graphic graphic_table graphicRef128074" href="/z/d/graphic/128074.html" rel="external">table 2</a>) is a reasonable alternative. (See <a class="local">'Choice of chemotherapy regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radical cystectomy after neoadjuvant chemotherapy </strong>– At the completion of neoadjuvant chemotherapy, all patients should proceed with radical cystectomy, even if they have had a complete response to neoadjuvant therapy. Although it may eventually be possible to identify patients who may not require cystectomy at the end of neoadjuvant chemotherapy, the data to support a tailored postneoadjuvant surgical approach are limited. We and others consider bladder preservation inferior to radical cystectomy when attempting to achieve cure. (See <a class="local">'Radical cystectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternatives to cystectomy </strong>– Bladder-sparing therapy may be considered a reasonable alternative to radical surgery in patients who are deemed unfit for cystectomy as well as for those seeking an alternative to radical cystectomy. (See  <a class="medical medical_review" href="/z/d/html/98344.html" rel="external">"Bladder preservation treatment options for muscle-invasive urothelial bladder cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment surveillance </strong>– For patients who have completed treatment for muscle-invasive bladder cancer, careful and structured follow-up is essential for detection of a recurrence (in the case of partial cystectomy or bladder preservation) or a second primary urothelial malignancy in the urogenital tract. (See <a class="local">'Posttreatment surveillance and treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1036786849"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Derek Raghavan, MD, PhD, FACP, FASCO, and Phillip W Kantoff, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on December 13, 2023).</li><li><a class="nounderline abstract_t">Apolo AB, Kim JW, Bochner BH, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol 2014; 32:637.</a></li><li><a class="nounderline abstract_t">Audenet F, Sfakianos JP, Waingankar N, et al. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urol Oncol 2019; 37:116.</a></li><li><a class="nounderline abstract_t">Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361:1927.</a></li><li><a class="nounderline abstract_t">Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62:523.</a></li><li><a class="nounderline abstract_t">Pfister C, Gravis G, Fléchon A, et al. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol 2021; 79:214.</a></li><li><a class="nounderline abstract_t">Pfister C, Gravis G, Fléchon A, et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol 2022; 40:2013.</a></li><li><a class="nounderline abstract_t">Soto Parra H, Cavina R, Latteri F, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002; 13:1080.</a></li><li class="breakAll">Abdelhafez M, William M. Safety and efficacy Gemcitabine-Cisplatin split dose as a neoaduvant chemotherapy for muscle invasive bladder cancer. Presented at the 2017 American Urologic Association Annual Meeting. https://www.auajournals.org/doi/10.1016/j.juro.2017.02.2776 (Accessed on September 07, 2023).</li><li><a class="nounderline abstract_t">Hussain SA, Palmer DH, Lloyd B, et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett 2012; 3:855.</a></li><li><a class="nounderline abstract_t">Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533.</a></li><li><a class="nounderline abstract_t">Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and neck cancer. Version 1.2021. Available at: https://www.nccn.org/professionals/physician_gls/ (Accessed on January 20, 2021).</li><li><a class="nounderline abstract_t">Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 2015; 121:2586.</a></li><li><a class="nounderline abstract_t">Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015; 67:241.</a></li><li><a class="nounderline abstract_t">Flaig TW, Tangen CM, Daneshmand S, et al. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res 2021; 27:2435.</a></li><li><a class="nounderline abstract_t">Liu T, Jiang G. A systematic review and meta-analysis of neoadjuvant chemotherapy for bladder cancer between ddMVAC and GC regimen. Urol Oncol 2022; 40:195.e19.</a></li><li><a class="nounderline abstract_t">Chung DY, Kang DH, Kim JW, et al. Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Culine S, Harter V, Gravis G, et al. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clin Genitourin Cancer 2021; 19:554.</a></li><li><a class="nounderline abstract_t">Flaig TW, Tangen C, Daneshmand S, et al. SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up. J Clin Oncol 2022; 40;6S.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014; 32:1889.</a></li><li><a class="nounderline abstract_t">Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014; 32:1895.</a></li><li><a class="nounderline abstract_t">Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19:2638.</a></li><li><a class="nounderline abstract_t">Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50.</a></li><li><a class="nounderline abstract_t">International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29:2171.</a></li><li><a class="nounderline abstract_t">Mertens LS, Meijer RP, Kerst JM, et al. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients? J Urol 2012; 188:1108.</a></li><li><a class="nounderline abstract_t">Russell PJ, Raghavan D, Gregory P, et al. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res 1986; 46:2035.</a></li><li><a class="nounderline abstract_t">Raghavan D. Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer 2003; 97:2050.</a></li><li><a class="nounderline abstract_t">Trump DL, Elson P, Madajewicz S, et al. Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group. J Urol 1990; 144:1119.</a></li><li><a class="nounderline abstract_t">Raabe NK, Fossa SD, Parø G. Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. Br J Urol 1989; 64:604.</a></li><li><a class="nounderline abstract_t">Hansen PV, Glavind K, Panduro J, Pedersen M. Paternity in patients with testicular germ cell cancer: pretreatment and post-treatment findings. Eur J Cancer 1991; 27:1385.</a></li><li><a class="nounderline abstract_t">Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80:1966.</a></li><li><a class="nounderline abstract_t">Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19:2527.</a></li><li><a class="nounderline abstract_t">Ording AG, Nielsen ME, Smith AB, et al. Venous thromboembolism and effect of comorbidity in bladder cancer: A danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011. Urol Oncol 2016; 34:292.e1.</a></li><li><a class="nounderline abstract_t">Duivenvoorden WC, Daneshmand S, Canter D, et al. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. J Urol 2016; 196:1627.</a></li><li><a class="nounderline abstract_t">Einerhand SMH, van Dijk N, van Dorp J, et al. Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer. Int J Cancer 2022; 151:2004.</a></li><li><a class="nounderline abstract_t">Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25:1706.</a></li><li><a class="nounderline abstract_t">Szabados B, Kockx M, Assaf ZJ, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol 2022; 82:212.</a></li><li><a class="nounderline abstract_t">Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2018; 36:3353.</a></li><li><a class="nounderline abstract_t">Necchi A, Raggi D, Gallina A, et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Eur Urol 2020; 77:439.</a></li><li><a class="nounderline abstract_t">Bandini M, Gibb EA, Gallina A, et al. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆. Ann Oncol 2020; 31:1755.</a></li><li><a class="nounderline abstract_t">Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 2020; 26:1845.</a></li><li><a class="nounderline abstract_t">van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 2020; 26:1839.</a></li><li><a class="nounderline abstract_t">Rose TL, Harrison MR, Deal AM, et al. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol 2021; 39:3140.</a></li><li><a class="nounderline abstract_t">Funt SA, Lattanzi M, Whiting K, et al. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol 2022; 40:1312.</a></li><li><a class="nounderline abstract_t">Gupta S, Sonpavde G, Weight CJ, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol 2020; 38;6S.</a></li><li><a class="nounderline abstract_t">Whitmore WF Jr, Batata MA, Ghoneim MA, et al. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 1977; 118:184.</a></li><li><a class="nounderline abstract_t">Shipley WU, Cummings KB, Coombs LJ, et al. 4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: a prospective study of patient tolerance and pathologic downstaging. J Urol 1982; 127:48.</a></li><li><a class="nounderline abstract_t">Cole CJ, Pollack A, Zagars GK, et al. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995; 32:331.</a></li><li><a class="nounderline abstract_t">Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 1982; 54:136.</a></li><li><a class="nounderline abstract_t">deVere White RW, Lara PN Jr, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 2009; 181:2476.</a></li><li><a class="nounderline abstract_t">Sternberg CN, Pansadoro V, Calabrò F, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003; 97:1644.</a></li><li><a class="nounderline abstract_t">Robins D, Matulay J, Lipsky M, et al. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. Urology 2018; 111:116.</a></li><li><a class="nounderline abstract_t">Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666.</a></li><li><a class="nounderline abstract_t">Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259.</a></li><li><a class="nounderline abstract_t">Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13:1384.</a></li><li><a class="nounderline abstract_t">Herr HW, Bajorin DF, Scher HI, et al. Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol 1999; 161:20.</a></li><li><a class="nounderline abstract_t">Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A:2243.</a></li><li><a class="nounderline abstract_t">Tsuji M, Kojima K, Murakami Y, et al. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997; 79:367.</a></li><li><a class="nounderline abstract_t">Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29:3443.</a></li><li><a class="nounderline abstract_t">Garcia del Muro X, Condom E, Vigués F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004; 100:1859.</a></li><li><a class="nounderline abstract_t">Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11:2625.</a></li><li><a class="nounderline abstract_t">Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011; 12:137.</a></li><li><a class="nounderline abstract_t">Seiler R, Ashab HAD, Erho N, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol 2017; 72:544.</a></li><li><a class="nounderline abstract_t">Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014; 4:1140.</a></li><li><a class="nounderline abstract_t">Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol 2015; 68:959.</a></li><li><a class="nounderline abstract_t">Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558.</a></li><li><a class="nounderline abstract_t">McDaniel AS, Alva A, Zhan T, et al. Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. Eur Urol Focus 2016; 1:265.</a></li></ol></div><div id="topicVersionRevision">Topic 2991 Version 70.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://gco.iarc.fr/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on December 13, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24840869" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509868" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A delay≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12801735" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22677572" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32868138" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35254888" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176787" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176787" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22741006" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10470696" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944571" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944571" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25872978" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25257030" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33568346" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34949512" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A systematic review and meta-analysis of neoadjuvant chemotherapy for bladder cancer between ddMVAC and GC regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34199565" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34602349" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821883" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821881" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11352955" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330205" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502557" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901581" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2418959" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bladder cancer xenografts: a model of tumor cell heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12673696" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Progress in the chemotherapy of metastatic cancer of the urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2231883" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2697452" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1835852" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Paternity in patients with testicular germ cell cancer: pretreatment and post-treatment findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366300" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11331332" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26971189" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Venous thromboembolism and effect of comorbidity in bladder cancer: A danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27312316" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35603905" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31686036" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35577646" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30343614" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31708296" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32979511" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046869" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33046870" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34428076" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35089812" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/875217" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Radical cystectomy with or without prior irradiation in the treatment of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7057503" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: a prospective study of patient tolerance and pathologic downstaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751174" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7044462" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371909" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12655521" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Can patient selection for bladder preservation be based on response to chemotherapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032239" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157016" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935683" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Accumulation of nuclear p53 and tumor progression in bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751883" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037358" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Can p53 help select patients with invasive bladder cancer for bladder preservation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652250" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : p53 overexpression as a prognostic factor for advanced stage bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9117215" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810677" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15112266" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814643" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21256081" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28390739" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096233" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26238431" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428503" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723397" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
